Ciprodex · DIN 02252716 · 0.3% w/v & 0.1% w/v · Otic suspension-7.5mL Pk (With Preservative)
Limited Use, Reason for Use code 509 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 509 required
Write on scriptReason for Use code 509 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 509
Reason for Use code 509
The treatment of otitis externa in patients:
- With known perforated tympanic membrane or ventilation tubes;
OR
- Requiring chronic therapy (i.e., more than 14 days);
OR
- Who have been receiving more than 7 days of topical aminoglycoside therapy without improvement, where there is concern of a resistant pathogen;
OR
- With documented pre-existing hearing impairment.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Ciprodex · DIN 02252716
Manufacturer: Novartis Pharma Canada Inc.; listing date 2018-06-29
Health Canada: Marketed since 2018-06-11 · brand CIPRODEX · ATC S02CA06 DEXAMETHASONE AND ANTIINFECTIVES · form Suspension · route Otic · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 0.3 %/W/V, DEXAMETHASONE 0.1 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
Ministry pays: $14.4203 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02252716)
Source record
DIN 02252716: Ciprodex
Raw flags: sec12=Y, sec3=Y
Item: 520404046; group id 575; item number 1529; lccId 00306; manufacturer id NOV
Source form: Otic Susp-7.5mL Pk (With Preservative); strength: 0.3% w/v & 0.1% w/v
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $32.6094; ministry $14.4203
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02252716
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73758
Interchangeable products
Sandoz Ciprofloxacin/Dexamethasone · DIN 02506882 · $14.4203
Taro-Ciprofloxacin/Dexamethasone · DIN 02481901 · $14.4203
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02252716
Shortage record checked October 6, 2026